An European Post-Authorization Safety Study (PASS) study of SCENESSE in adult erythropoietic protoporphyria patients

Trial Profile

An European Post-Authorization Safety Study (PASS) study of SCENESSE in adult erythropoietic protoporphyria patients

Not stated
Phase of Trial: Phase IV

Latest Information Update: 05 Apr 2018

At a glance

  • Drugs Afamelanotide (Primary)
  • Indications Erythropoietic protoporphyria
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Apr 2018 New trial record
    • 19 Mar 2018 According to a Clinuvel Pharmaceuticals media release, analyses of clinical effectiveness are being conducted for those EPP patients who continue treatment and those who received their first treatment after 30 June 2017. Data from this study discussed at the third European meeting on erythropoietic protoporphyria (EPP).
    • 19 Mar 2018 Results published in the Clinuvel Pharmaceuticals Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top